Group One Trading
YMAB

Group One Trading’s Y-mAbs Therapeutics YMAB Stock Holding History

Group One Trading’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-300
Closed -$1.33K – 8766
2025
Q1 		$1.33K Sell
300
-400
-57% -$2.32K ﹤0.01% 7110
2024
Q4 		$5.48K Buy
700
+300
+75% +$3.65K ﹤0.01% 6383
2024
Q3 		$5.26K Sell
400
-6,400
-94% -$81.1K ﹤0.01% 5861
2024
Q2 		$82.1K Hold
6,800
– – ﹤0.01% 4119
2024
Q1 		$111K Buy
+6,800
New +$91.6K ﹤0.01% 4073
2023
Q2 		– Sell
-600
Closed -$3.01K – 8288
2023
Q1 		$3.01K Buy
+600
New +$2.45K ﹤0.01% 6492
2022
Q3 		– Sell
-7,200
Closed -$109K – 8355
2022
Q2 		$109K Buy
7,200
+6,000
+500% +$70K ﹤0.01% 4912
2022
Q1 		$14K Buy
+1,200
New +$12.3K ﹤0.01% 7016

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Group One Trading's YMAB Position: Q2 2022 in Review

Group One Trading sold out of Y-mAbs Therapeutics (YMAB) in Q2 2022, closing a stake of 100 shares — an estimated $1.17K sold.

Group One Trading first reported a position in YMAB in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 91 funds tracked by Wall St. Rank hold YMAB as of Q2 2022.

  • Group One Trading reported no remaining Y-mAbs Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Group One Trading sold 100 Y-mAbs Therapeutics shares in Q2 2022, an estimated $1.17K.
  • Group One Trading first reported a position in Y-mAbs Therapeutics in Q1 2022 and held it in 1 quarter.
  • Group One Trading's Y-mAbs Therapeutics position peaked at $1K in Q1 2022.
  • 91 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2022.

Based on Group One Trading's 13F filing for Q2 2022, filed 11 Aug 2022.